New 3-amino-2-thioxothiazolidin-4-one-based inhibitors of acetyl- and butyryl-cholinesterase: synthesis and activity

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mousavi SM, Zarei M, Hashemi SA, Babapoor A, Amani AM. A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities. Artif. Cells Nanomed. Biotechnol. 47, 1132–1148 (2019). • A review dealing with antimicrobial and anticancer action of 5-arylidene rhodanines and their analogues.
  Medline CASGoogle Scholar
• 2. Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-Ene-4-thiazolidinones: an efficient tool in medicinal chemistry. Eur. J. Med. Chem. 140, 542–594 (2017). •• A comprehensive review dealing with an overview of synthesis and biological activity of 5-arylidene substituted rhodanines.
  Medline CASGoogle Scholar
• 3. Krátký M, Štěpánková Š, Vorčáková K, Vinšová J. Synthesis and in vitro evaluation of novel rhodanine derivatives as potential cholinesterase inhibitors. Bioorg. Chem. 68, 23–29 (2016). • An article reporting, for the first-time, esters and amides of rhodanine-3-acetic acid as inhibitors of cholinesterases.
  Medline CASGoogle Scholar
• 4. Krátký M, Sramel P, Bodo P et al. Novel rhodanine based inhibitors of aldose reductase of non-acidic nature with p-hydroxybenzylidene functional group. Eur. J. Med. Chem. 246, 114922 (2023).
  Medline CASGoogle Scholar
• 5. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J. Med. Chem. 55, 743–753 (2012).
  Medline CASGoogle Scholar
• 6. Tomašić T, Mašić LP. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opin. Drug Discov. 7, 549–560 (2012).
  Medline CASGoogle Scholar
• 7. Arsovska E, Trontelj J, Zidar N et al. Evaluation of Michael-type acceptor reactivity of 5-benzylidenebarbiturates, 5-benzylidenerhodanines, and related heterocycles using NMR. Acta Chim. Slov. 61, 637–644 (2014).
  Medline CASGoogle Scholar
• 8. Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin. Drug Discov. 12, 1233–1252 (2017). •• A comprehensive review dealing with recent advances related to 5-arylidene substituted rhodanines, including discussion of their controversies.
  Medline CASGoogle Scholar
• 9. Krátký M, Vu QA, Štěpánková Š et al. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: synthesis, biological evaluation and docking study. Bioorg. Chem. 116, 105301 (2021).
  Medline CASGoogle Scholar
• 10. Brem J, van Berkel SS, Aik W et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat. Chem. 6, 1084–1090 (2014). • A paper reporting a ‘nonclassical’ mechanism of action of 5-arylidene rhodanine (as a prodrug).
  Medline CASGoogle Scholar
• 11. Čolović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr. Neuropharmacol. 11, 315–335 (2013).
  Medline CASGoogle Scholar
• 12. Swetha R, Kumar D, Gupta SK et al. Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimer's disease. Future Med. Chem. 11(24), 3161–3178 (2019).
  CASGoogle Scholar
• 13. Hameed S, Babatunde O, Salar U et al. Efficient one-pot synthesis of arylated pyrazole-fused pyran analogs: as leads to treating diabetes and Alzheimer's disease. Future Med. Chem. 14(21), 1507–1526 (2022).
  CASGoogle Scholar
• 14. Smyrska-Wieleba N, Mroczek T. Natural inhibitors of cholinesterases: chemistry, structure–activity and methods of their analysis. Int. J. Mol. Sci. 24(3), 2722 (2023).
  Medline CASGoogle Scholar
• 15. Zhou S, Huang G. The biological activities of butyrylcholinesterase inhibitors. Biomed. Pharmacother. 146, 112556 (2022).
  Medline CASGoogle Scholar
• 16. Obaid RJ, Naeem N, Mughal EU et al. Inhibitory potential of nitrogen, oxygen and sulfur containing heterocyclic scaffolds against acetylcholinesterase and butyrylcholinesterase. RSC Adv. 12, 19764–19855 (2022).
  Medline CASGoogle Scholar
• 17. Shafii N, Khoobi M, Amini M et al. Synthesis and biological evaluation of 5-benzylidenerhodanine-3-acetic acid derivatives as AChE and 15-LOX inhibitors. J. Enzyme Inhib. Med. Chem. 30, 389–395 (2015).
  Medline CASGoogle Scholar
• 18. Bayindir S, Caglayan C, Karaman M, Gülcin İ. The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes. Bioorg. Chem. 90, 103096 (2019).
  Medline CASGoogle Scholar
• 19. Krátký M, Štěpánková Š, Brablíková M, Svrčková K, Švarcová M, Vinšová J. Novel iodinated hydrazide-hydrazones and their analogues as acetyl- and butyrylcholinesterase inhibitors. Curr. Top. Med. Chem. 20, 2106–2117 (2020).
  Medline CASGoogle Scholar
• 20. Krátký M, Svrčková K, Vu QA, Štěpánková Š, Vinšová J. Hydrazones of 4-(trifluoromethyl)benzohydrazide as new inhibitors of acetyl- and butyrylcholinesterase. Molecules 26, 989 (2021).
  Medline CASGoogle Scholar
• 21. Yılmaz S, Akbaba Y, Özgeriş B et al. Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase. J. Enzyme Inhib. Med. Chem. 31, 1484–1491 (2016).
  Medline CASGoogle Scholar
• 22. Karaman M, Temel Y, Bayindir S. Inhibition effect of rhodanines containing benzene moieties on pentose phosphate pathway enzymes and molecular docking. J. Mol. Struct. 1220, 128700 (2020).
  CASGoogle Scholar
• 23. Nederlof A. The preparation and reactions of some rhodanines. Recl. Trav. Chim. Pays-Bas 82, 75–89 (1963).
  Google Scholar
• 24. Tabatabaee M, Heravi MM, Sharif M, Esfandiyari F. Fast and efficient method for imination of N-aminorhodanine using inorganic solid support under microwave irradiation and classical heating. E-J. Chem. 8, 535–540 (2011).
  CASGoogle Scholar
• 25. Turkevich NM, Petlichnaya LI. UV absorption spectra of 3-aminorhodanine derivatives. Chem. Heterocycl. Compd. 7, 1111–1113 (1971).
  Google Scholar
• 26. Powers JP, Piper DE, Li Y et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem. 49, 1034–1046 (2006).
  Medline CASGoogle Scholar
• 27. Zdrazilova P, Stepankova S, Komers K, Ventura K, Cegan A. Half-inhibition concentrations of new cholinesterase inhibitors. Z. Naturforsch. C 59, 293–296 (2004).
  Medline CASGoogle Scholar
• 28. Lineweaver H, Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56, 658–666 (1934).
  CASGoogle Scholar
• 29. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
  Medline CASGoogle Scholar
• 30. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010).
  Medline CASGoogle Scholar
• 31. Morris GM, Huey R, Lindstrom W et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791 (2009).
  Medline CASGoogle Scholar
• 32. Park S, Lee H, Yi Y, Lim MH, Kim C. A rhodanine-based fluorescent chemosensor for sensing Zn²⁺ and Cd²⁺: applications to water sample and cell imaging. Inorganica Chim. Acta 513, 119936 (2020).
  CASGoogle Scholar
• 33. Sinko G, Calic M, Bosak A, Kovarik Z. Limitation of the Ellman method: cholinesterase activity measurement in the presence of oximes. Anal. Biochem. 370, 223–227 (2007).
  Medline CASGoogle Scholar
• 34. Kandiah N, Pai M, Senanarong V et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin. Interv. Aging 12, 697–707 (2017).
  Medline CASGoogle Scholar
• 35. Ryan AJ, Gray NM, Lowe PN, Chung C. Effect of detergent on “promiscuous” inhibitors. J. Med. Chem. 46, 3448–3451 (2003).
  Medline CASGoogle Scholar
• 36. Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: from 3D structure to function. Chem. Biol. Interact. 187, 10–22 (2010).
  Medline CASGoogle Scholar
• 37. Ordentlich A, Barak D, Kronman C et al. Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase. J. Biol. Chem. 270, 2082–2091 (1995).
  Medline CASGoogle Scholar
• 38. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept^®): implications for the design of new anti-Alzheimer drugs. Structure 7, 297–307 (1999).
  Medline CASGoogle Scholar
• 39. Silva LB, Ferreira EFB, Maryam et al. Galantamine based novel acetylcholinesterase enzyme inhibitors: a molecular modeling design approach. Molecules 28, 1035 (2023).
  Medline CASGoogle Scholar
• 40. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278, 41141–41147 (2003).
  Medline CASGoogle Scholar